Search

Your search keyword '"Tumors -- Drug therapy -- Genetic aspects"' showing total 3 results
Start Over Descriptor "Tumors -- Drug therapy -- Genetic aspects" Journal globenewswire
3 results on '"Tumors -- Drug therapy -- Genetic aspects"'

1. PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation

Subjects
United States. Food and Drug Administration, Cancer treatment, Tumor proteins -- Genetic aspects -- Drug therapy, Tumors -- Drug therapy -- Genetic aspects, Cancer patients -- Drug therapy, Drug approval, Banking, finance and accounting industries, Business
Abstract

CRANBURY, N.J., Oct 13, 2020 (GLOBE NEWSWIRE via COMTEX) -- PMV Pharmaceuticals, Inc., (Nasdaq: PMVP) a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting [...]

Published
2020

2. Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors

Subjects
United States. Food and Drug Administration, Chemotherapy, Tumors -- Drug therapy -- Genetic aspects, Banking, finance and accounting industries, Business
Abstract

SAN DIEGO, Aug 24, 2020 (GLOBE NEWSWIRE via COMTEX) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today [...]

Published
2020

3. Black Diamond Therapeutics Granted Fast Track Designation by the FDA for BDTX-189 for the Treatment of Adult Patients with a Solid Tumor Harboring an Allosteric HER2 Mutation or an EGFR or HER2 Exon 20 Insertion Mutation

Subjects
United States. Food and Drug Administration, Tumors -- Drug therapy -- Genetic aspects, Epidermal growth factors -- Genetic aspects, Banking, finance and accounting industries, Business
Abstract

CAMBRIDGE, Jul 28, 2020 (GLOBE NEWSWIRE via COMTEX) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results